We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO Latin America Conference
September 4-5, 2018
BIO Investor Forum
October 17-18, 2018
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
October 17 - 18, 2018 | San Francisco, California
Peter Noymer, PhD, joined Kedalion Therapeutics in 2017 as President and CEO, leading a team advancing novel therapies for topical ocular delivery using the proprietary AcuStream platform. Prior to Kedalion, Peter was Chief Operating Officer at SteadyMed, responsible for the development and scale-up of a cardiovascular therapy based on a novel, prefilled, wearable infusion system that received Orphan Drug Designation from the FDA. Earlier, he served as VP of Product R&D at Alexza Pharmaceuticals, obtaining FDA and EMA approval for Adasuve®, the first inhalable treatment for acute agitation. Peter also served in management roles at Aradigm Corporation, taught at Carnegie Mellon University and held engineering positions at GE. Dr. Noymer received MS and PhD degrees from MIT, and a BS degree from Princeton University.
This speaker's sessions: